Ocrevus (Ocrelizumab)

Ocrelizumab, the active ingredient in Ocrevus, is a monoclonab presented as a / for intravenous use. It treats multiple sclerosis in adult patients.

GNH USA supplies Ocrevus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Ocrevus is a disease‑modifying therapy that targets B‑cell activity in multiple sclerosis.

- Relapsing‑remitting multiple sclerosis: Reduces the frequency of clinical relapses and slows the accumulation of disability by prevent ­     -          

Common     

Check